source
- Travere pays Everest $112M upfront to grow rare kidney disease pipelineTravere Therapeutics is enlisting the help of China-based Everest Medicines to bolster its rare kidney disease pipeline beyond its approved medicine Filspari. The San Diego biotech is doling out $1…Endpoints · 1mo ago↗ source
- Legend Biotech shares first in vivo CAR-T data, its next act after CarvyktiLegend Biotech’s long-awaited first showing of in vivo CAR-T data is here, fueling momentum in the growing field. Legend reported results Tuesday on 12 lymphoma patients from an investigator-initia…Endpoints · 1mo ago↗ source
- STAT+: Pharmalittle: We’re reading about a Lilly threat to 340B hospitals, Ebola vaccine funding, and moreLilly gave hospitals participating in a federal drug discount program five days to submit claims data or it will stop the price breaks